LLY

1,033.61

+0.76%↑

JNJ

199.21

-0.26%↓

ABBV

234.56

+0.18%↑

UNH

312.14

-3.9%↓

AZN

89.35

-0.43%↓

LLY

1,033.61

+0.76%↑

JNJ

199.21

-0.26%↓

ABBV

234.56

+0.18%↑

UNH

312.14

-3.9%↓

AZN

89.35

-0.43%↓

LLY

1,033.61

+0.76%↑

JNJ

199.21

-0.26%↓

ABBV

234.56

+0.18%↑

UNH

312.14

-3.9%↓

AZN

89.35

-0.43%↓

LLY

1,033.61

+0.76%↑

JNJ

199.21

-0.26%↓

ABBV

234.56

+0.18%↑

UNH

312.14

-3.9%↓

AZN

89.35

-0.43%↓

LLY

1,033.61

+0.76%↑

JNJ

199.21

-0.26%↓

ABBV

234.56

+0.18%↑

UNH

312.14

-3.9%↓

AZN

89.35

-0.43%↓

Inicio・Lista de Acciones・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Abierto

SectorSalud

8.73 -2.02

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

8.65

Máximo

9.06

Métricas clave
By Trading Economics
Ingresos	11M -20M
Ventas	5.9M 40M
BPA	-0.19
Margen de beneficio	-49.569
Empleados	184
EBITDA	16M -19M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+167.84% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	294M 1B
Apertura anterior	10.75
Cierre anterior	8.73

Noticias sobre sentimiento de mercado

By Acuity

50%

185 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

6.26 / 7.47 Soporte y Resistencia

Day One Biopharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

17 nov 2025, 18:59 UTC

Principales Movimientos del Mercado

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17 nov 2025, 23:40 UTC

Charlas de Mercado

Gold Consolidates Amid Mixed Signals -- Market Talk

17 nov 2025, 23:34 UTC

Charlas de Mercado

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17 nov 2025, 22:58 UTC

Charlas de Mercado

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17 nov 2025, 22:46 UTC

Charlas de Mercado

Risk Assets Set to Have a Strong 2026 -- Market Talk

17 nov 2025, 22:06 UTC

Adquisiciones, fusiones, absorciones

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17 nov 2025, 22:02 UTC

Ganancias

Trip.com Group 3Q Rev $2.6B >TCOM

17 nov 2025, 22:02 UTC

Ganancias

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17 nov 2025, 22:02 UTC

Ganancias

Trip.com Group 3Q EPS $4.02 >TCOM

17 nov 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 nov 2025, 21:40 UTC

Ganancias

James Hardie Industries 2Q Adj EPS 26c >JHX

17 nov 2025, 21:40 UTC

Ganancias

James Hardie Industries 2Q Loss/Shr 10c >JHX

17 nov 2025, 21:39 UTC

Ganancias

James Hardie Industries 2Q Sales $1.29B >JHX

17 nov 2025, 21:38 UTC

Ganancias

Adquisiciones, fusiones, absorciones

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 21:38 UTC

Ganancias

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17 nov 2025, 21:10 UTC

Ganancias

XP Inc. 3Q EPS BRL2.47 >XP

17 nov 2025, 21:10 UTC

Ganancias

XP Inc. 3Q Rev BRL4.67B >XP

17 nov 2025, 20:20 UTC

Charlas de Mercado

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17 nov 2025, 20:12 UTC

Charlas de Mercado

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17 nov 2025, 20:12 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 nov 2025, 20:09 UTC

Charlas de Mercado

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17 nov 2025, 19:29 UTC

Charlas de Mercado

Gold Slide Continues to Start Week -- Market Talk

17 nov 2025, 19:16 UTC

Ganancias

Adquisiciones, fusiones, absorciones

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 18:20 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17 nov 2025, 16:45 UTC

Adquisiciones, fusiones, absorciones

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17 nov 2025, 16:16 UTC

Ganancias

Adquisiciones, fusiones, absorciones

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 16:15 UTC

Ganancias

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17 nov 2025, 15:40 UTC

Adquisiciones, fusiones, absorciones

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17 nov 2025, 15:22 UTC

Adquisiciones, fusiones, absorciones

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17 nov 2025, 15:19 UTC

Charlas de Mercado

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Comparación entre iguales

Cambio de precio

Day One Biopharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

167.84% repunte

Estimación a 12 meses

Media 23.57 USD 167.84%

Máximo 34 USD

Mínimo 16 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Day One Biopharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Day One Biopharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

6.26 / 7.47Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Sentimiento

By Acuity

185 / 374 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.